Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

被引：4
|
作者：
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8028
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Weisel, Katja
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth Carl
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Shelat, Suresh
    Sy, Oumar
    Singhal, Anil K.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Dimopoulos, Meletios
    Weisel, Katja
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San Miguel, Jesus
    Anderson, Kenneth
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Shelat, Suresh
    Sy, Oumar
    Singhal, Anil
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S253 - S253
  • [3] Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 35 - 35
  • [4] PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [5] Phase 3 ELOQUENT-2 study extended 5-y follow-up comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with Ld to treat relapsed/refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M-, V
    San Miguel, J.
    Anderson, K.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I
    Walter-Cronek, A.
    Magen, H.
    Belch, A.
    Reece, D.
    Beksac, M.
    Shelat, S. G.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 230 - 230
  • [6] ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M. -V
    Belch, A.
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A. K.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 123
  • [7] ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomidefdexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)-Identifying responders by subset analysis.
    Lonial, Sagar
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Weisel, Katja
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Sy, Oumar
    Katz, Jessica
    Gupta, Manish
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] ELOQUENT-2: Extended safety and efficacy follow-up of the phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M-V
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A.
    Richardson, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 6 - 7
  • [9] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth C.
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Ganetsky, Alex
    Jou, Ying-Ming
    McKiver, Mihaela Popa
    Singhal, Anil K.
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
  • [10] Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study
    Cella, David
    McKendrick, Jan
    Davis, Harrison
    Vij, Ravi
    Chen, Clara
    BLOOD, 2019, 134
12345